Deutsche Bank Ag\ Kal Vista Pharmaceuticals, Inc. Transaction History
Deutsche Bank Ag\
- $240 Billion
- Q3 2024
A detailed history of Deutsche Bank Ag\ transactions in Kal Vista Pharmaceuticals, Inc. stock. As of the latest transaction made, Deutsche Bank Ag\ holds 21,918 shares of KALV stock, worth $196,385. This represents 0.0% of its overall portfolio holdings.
Number of Shares
21,918
Previous 15,858
38.21%
Holding current value
$196,385
Previous $186,000
36.02%
% of portfolio
0.0%
Previous 0.0%
Shares
32 transactions
Others Institutions Holding KALV
# of Institutions
125Shares Held
47.8MCall Options Held
551KPut Options Held
110K-
Vr Adviser, LLC New York, NY6.25MShares$56 Million7.5% of portfolio
-
Tang Capital Management LLC San Diego, CA4.32MShares$38.7 Million4.26% of portfolio
-
Suvretta Capital Management, LLC New York, NY4.21MShares$37.7 Million1.92% of portfolio
-
Vestal Point Capital, LP New York, NY4MShares$35.8 Million3.51% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.69MShares$33 Million2.3% of portfolio
About KalVista Pharmaceuticals, Inc.
- Ticker KALV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,602,000
- Market Cap $220M
- Description
- KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral p...